Immuno-Oncology Applications of Myeloid-Supportive Humanized Immune System Mice
Humanized immune system (HIS) mice have been widely adopted in immuno-oncology research due to their capability of modeling human immune response to immune-modulating therapeutics. Myeloid cell-supportive HIS mice are proving to be invaluable for advancing immuno-oncology applications and extending immunotherapeutic efficacy trials beyond T cells to other immune cells for discovering the next cancer breakthrough.
Myeloid cells are being targeted for immuno-oncology research due to the important role they play in the innate immune response and because of their ability to serve immune regulatory functions. HIS mice which support the development of human myeloid cells can be used to explore new therapeutic mechanisms focused on the manipulation of immune cells, including monocyte and granulocyte lineages: macrophages, dendritic cells, mast cells, basophils, eosinophils, and neutrophils.
Register for the webinar to hear from Ivan Gladwyn-Ng (B.Sc.(Med.), PhD, a Taconic Field Application Scientist, about how myeloid-supporting HIS mice can be applied to investigate different mechanistic strategies for immunotherapy involving myeloid cells, including immune checkpoint inhibition, cancer vaccines, adoptive cell transfer, and more. Attendees will learn how:
- Following tumor implantation in HIS mice, human immune cells of both lymphoid and myeloid lineages infiltrate tumors, making the study of specific tumor-infiltrating lymphocyte types possible.
- HIS mice cells enable the study of human tumor influence on the specific intratumoral immune cell composition (lymphocytes, macrophages, granulocytes).
- HIS mice containing both human lymphoid and myeloid lineages can be used to study the mechanisms of combination therapies targeting PD-1 and LAG3 as a strategy to improve response to anti-PD-1 drugs.
- Certain myeloid-supportive HIS mice promote the development of plasmacytoid dendritic cells, a rare human cell type, which play a role in regulating the immunosuppressive functions of Tregs.
- Myeloid-supportive HIS mice can be applied to new aspects of immunotherapy development.
Ivan Gladwyn-Ng (B.Sc.(Med.), PhD
Field Application Scientist | Taconic Biosciences
Ivan Gladwyn-Ng (B.Sc.(Med.), PhD, is a Field Application Scientist at Taconic Biosciences who has utilized rodent models within many diverse fields of preclinical research for more than a decade. He is passionate about accelerating advancements in human health by improving the care and application of in vivo animal models in the drug discovery process. He is particularly interested in the studies of infectious, oncological, metabolic, and neurological diseases. Ivan has led multi-disciplinary research teams with global collaborations in laboratories from diverse parts of the world, as adjunct researcher and post-doctoral research fellow in the Institut Pasteur (Paris, France), Harry Perkins Institute of Medical Research (Perth, Australia) and the GIGA Institute (Liege, Belgium) with successful co-first and corresponding authorships in Nature Research, Cell Press, Science and Frontiers publications as well as successful patent applications in Europe and USA. Prior to these, he was conferred his doctorate at the Australian Regenerative Medicine Institute (Melbourne, Australia), after completing the sale of his start-up company, with First-Class Honours (top student) after completing his undergraduate studies (B.Sc. (Med.) at Monash University.